Development and validation of a disulfidptosis-related scoring system to predict clinical outcome and immunotherapy response in acute myeloid leukemia by integrated analysis of single-cell and bulk RNA-sequencing.

导出 LinkOut

翻译打印收藏纠错

第一作者： Fangmin,Zhong

第一单位： Department of Clinical Laboratory, Second Affiliated Hospital of Nanchang University, Nanchang, China.

作者： Fangmin,Zhong ^[1] ; Junyao,Jiang ^[1] ; Fang-Yi,Yao ^[1] ; Jing,Liu ^[1] ; Xu,Shuai ^[1] ; Xin-Lu,Wang ^[1] ; Bo,Huang ^[1] ; Xiaozhong,Wang ^[1]

作者单位： Department of Clinical Laboratory, Second Affiliated Hospital of Nanchang University, Nanchang, China. ^[1]

关键词 acute myeloid leukemia disulfidptosis immunotherapy prognosis tumor microenvironment

DOI 10.3389/fphar.2023.1272701

PMID 38053840

发布时间 2023-12-07

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Frontiers in pharmacology

2023年14卷

1272701页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Development and validation of a disulfidptosis-related scoring system to predict clinical outcome and immunotherapy response in acute myeloid leukemia by integrated analysis of single-cell and bulk RNA-sequencing.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Development and validation of a disulfidptosis-related scoring system to predict clinical outcome and immunotherapy response in acute myeloid leukemia by integrated analysis of single-cell and bulk RNA-sequencing.

Frontiers in pharmacology

相似文献

Frontiers in pharmacology

相关期刊

检索历史清除